ASCO-SEP® Medical Oncology Self-Evaluation Program 2024.pdf 9798988829423 ASCO

The latest updates to the Self-Evaluation Program (ASCO-SEP®), a 12-month digital subscription, include access to two valuable medical oncology board preparation tools created by leading medical oncology experts and designed with busy oncologists in mind. This year’s updates include:Revised 22 science and clinically based chapters and more than 1,300 questionsImproved features and personalization in the SEP Digital Edition and Question Bank. More Connected to Clinical Practice Written and peer-reviewed by more than 100 oncology experts, the 2024 ASCO-SEP Digital Edition features over 20 recently revised chapters with graphics; additionally, select chapters now contain clinical case studies with follow-up discussions. The author teams for each chapter carefully chose the case studies and aligned them with concepts that are likely to be seen in both practice and on board exams. Because of their relevance to clinical practice, oncology care team members can use these chapters for case prep and clinical rotation, and training programs can use them as a teaching tool by applying the content to real-world decision-making. The latest edition also features new high-yield takeaways in select chapters. Unlike the end-of-chapter summary key points, the high-yield takeaways emphasize the highest-priority items users are likely to see on exams. The takeaways were selected by the chapter authors as items that users should know how to identify immediately on a test. The 2024 Digital Edition will continue to feature chapter summary guides and stylistic features on all device types, including notetaking, highlighting, bookmarking, robust search, and the ability to download PDFs of each chapter. Question Bank Continues to Expand The ASCO-SEP Digital subscription includes access to its ever-growing Question Bank. The context- Cover LETTER FROM THE EDITOR Copyright Page CONTRIBUTORS CONTINUING EDUCATION AND CONFLICT OF INTEREST CHAPTER 1: EPIDEMIOLOGY AND PREVENTION CHAPTER 2: MOLECULAR BIOLOGY CHAPTER 3: CLINICAL PHARMACOLOGY CHAPTER 4: PRINCIPLES OF IMMUNO-ONCOLOGY AND BIOLOGIC THERAPY CHAPTER 5: CLINICAL TRIALS AND BIOSTATISTICS CHAPTER 6: GENETIC TESTING FOR HEREDITARY CANCER SYNDROMES CHAPTER 7: CANCER IN THE OLDER ADULT CHAPTER 8: PAIN AND SYMPTOM MANAGEMENT CHAPTER 9: PALLIATIVE CARE AND CARE AT THE END OF LIFE CHAPTER 10: BREAST CANCER CHAPTER 11: LUNG CANCER CHAPTER 12: HEAD AND NECK CANCERS CHAPTER 13: GASTROINTESTINAL CANCERS RECENT UPDATES GASTROESOPHAGEAL ADENOCARCINOMA COLORECTAL CANCER OVERVIEW GASTROESOPHAGEAL CANCER Fig. 13-1. Anatomic distribution of gastroesophageal cancers. EPIDEMIOLOGY, ETIOLOGY, AND PREVENTION ESOPHAGEAL ADENOCARCINOMA AND GEJ ADENOCARCINOMA GASTRIC ADENOCARCINOMA CLINICAL PRESENTATION, DIAGNOSIS, AND STAGING OF Fig. 13-2. Treatment algorithm based on clinical stage. TREATMENT SURGERY NEOADJUVANT, ADJUVANT, OR PERIOPERATIVE TREATMENT ESCC ESCC ESOPHAGEAL AND GEJ ADENOCARCINOMAS Table 13-1 Preferred Standard Curative-Intent Options of Perioperative Therapy for Locally AdvancedGastroesophageal Cancers Amenable for Surgery GASTRIC ADENOCARCINOMAS TREATMENT OF METASTATIC DISEASE ESOPHAGEAL, GEJ, AND GASTRIC ADENOCARCINOMAS HER2 OVEREXPRESSION–NEGATIVE ADENOCARCINOMAS HER2-POSITIVE GEA HER2 EXPRESSION TESTING CHAPTER 14: GENITOURINARY CANCERS CHAPTER 15: GYNECOLOGIC CANCERS CHAPTER 16: MELANOMA AND OTHER SKIN CANCERS CHAPTER 17: SARCOMA CHAPTER 18: CENTRAL NERVOUS SYSTEM TUMORS CHAPTER 19: LEUKEMIAS AND OTHER MYELOID NEOPLASMS CHAPTER 20: LYMPHOMAS CHAPTER 21: MULTIPLE MYELOMA CHAPTER 22: CELLULAR THERAPIES